IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma

IDEAYA Biosciences and Servier dosed the first patient in OptimUM-11, a global Phase 3 registrational trial of darovasertib plus crizotinib as 12-month adjuvant therapy for high-risk primary uveal melanoma. The approximately 450-patient trial will measure relapse-free survival versus observation in a setting with no approved adjuvant systemic treatment and where up to 50% of patients ultimately develop metastatic disease. IDEAYA also expects to complete its NDA submission in H2 2026 for the combination in first-line metastatic uveal melanoma, while sharing OptimUM-11 development costs with Servier.

Analysis

This is strategically positive for IDYA's lifecycle narrative but has little near-term valuation value: an adjuvant relapse-free-survival study in a rare disease will require enrollment, 12 months of treatment, and event accrual, making a meaningful readout unlikely before 2029. The market should not capitalize this indication materially today; the nearer value driver remains the metastatic filing/review, where regulatory acceptance, label breadth, and commercial assumptions can be tested on a much shorter horizon.

The meaningful second-order benefit is risk diversification rather than immediate revenue: success in adjuvant disease could expand treated duration and move darovasertib upstream, supporting a substantially larger lifetime patient-value pool than metastatic-only use. Conversely, the combination's tolerability is more consequential in an asymptomatic post-local-therapy population than in metastatic disease; even a clinically active regimen can fail adoption or a benefit-risk threshold if discontinuation rates are elevated. Crizotinib availability limits supply-chain risk, while Servier's ex-US economics reduce IDYA's ultimate international upside but also cap development-cost burden and execution risk.

Consensus may overread the first-patient milestone as de-risking efficacy. It does not establish that metastatic response translates into prevention of microscopic recurrence, and observation-controlled designs can amplify discontinuation and surveillance-bias scrutiny. The key falsifiers over the next 6-18 months are an unfavorable FDA review trajectory for metastatic disease, evidence of dose modification/discontinuation in ongoing combination studies, cash burn that shortens the runway before pivotal catalysts, or a narrower-than-expected metastatic label that weakens the platform's commercial proof point.

Key Decisions for Investors

• No incremental position solely on OptimUM-11 initiation; treat it as a 2029+ option value rather than a 1-3 month earnings catalyst.
• For biotech-risk capital, maintain or initiate a modest IDYA long only ahead of clearly dated metastatic NDA milestones over the next 3-9 months; size for binary regulatory and clinical volatility, with the thesis contingent on NDA completion/acceptance and no material safety signal.
• Use any press-release-driven IDYA strength to avoid chasing; add only if valuation retraces without a change in the metastatic regulatory timeline or combination tolerability disclosures.
• Monitor FDA filing acceptance, review designation/timing, cash runway, and discontinuation data from the metastatic and neoadjuvant programs. A delayed or refused-to-file outcome, or unexpectedly high treatment discontinuation, should trigger thesis reassessment rather than averaging down.
• FTRK has no discernible economic linkage to this development event; no trade implication.